Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
|Articles|May 11, 2016

BioTelemetry Acquires VirtualScopics

MALVERN, PA, May 11, 2016 - BioTelemetry, Inc. , the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that it has completed its acquisition of VirtualScopics, Inc., a leading provider of clinical trial imaging solutions. The acquisition comes after the successful completion of the all cash tender offer for all outstanding common and preferred shares of VirtualScopics. The total purchase consideration was approximately $15 million, net of cash and debt acquired.    Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, commented: “We are excited to welcome VirtualScopics to the BioTelemetry family. The addition of VirtualScopics’ imaging capabilities expands our clinical research offerings and further demonstrates our commitment to growing this important portion of our business. As I have mentioned in the past, an integrated cardiac and imaging testing platform will deliver much greater value to our customers and makes us a far more formidable competitor in this market. We are also thrilled to add a strong operational leadership team and look forward to building upon their longstanding customer relationships.”   The Company will provide additional information on the impact the acquisition will have on 2016 results during its normally scheduled second quarter earnings call which is expected to occur in late July.     About BioTelemetry   BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services. More information can be found at www.biotelinc.com.


Related to this article

What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.